Effects of 10 Versus 20 mL Local Anesthetic for Popliteal Plexus Block on Opioid Consumption, Pain, and Patient-Reported Outcomes After Total Knee Arthroplasty

NCT ID: NCT06908837

Last Updated: 2026-01-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-04-07

Study Completion Date

2025-11-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial aims to assess the analgesic effect of Popliteal Plexus Block (PPB) with 10 mL versus 20 mL of Bupivacain 5 mg/mL, when applied as an adjunct treatment to a multimodal analgesic regimen following primary total knee arthroplasty. We hypothesize that PPB with 20 mL of local anesthetic reduces 24-hour postoperative opioid consumption (= primary outcome) compared to 10 mL after TKA.

Secondary outcome include

* the frequency of 24-hour opioid-free analgesia
* pain intensity at rest and during mobilization
* Manual Muscle Tests and ability to mobilize with crutches six hours after end-of-surgery
* and patients reported outcomes using the Quality of Recovery 15 survey 24 hours after end-of-surgery.

Participant will:

* undergo primary total knee arthroplasty in spinal anesthesia.
* recieve a PPB with either 10 mL of Bupivacaine or 20 mL.
* recieve a multimodal analgesic regime including a Femoral Triangle Block.
* Have 10 scored morphine tablets available for self-administration within the first 24 postoperative hours after end-of-surgery.
* be examined by a physiotherapist 6 hours (±1 hour) after end-of-surgery to assess pain scores, manual muscle testing of ankle and knee function, and the ability to mobilize with crutches.
* complete a survey 24 hours after end-of-surgery to assess self-administered morphine intake, pain scores, and Quality of Recovery-15.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients will undergo primary unilateral total knee arthroplasty with insertion of non-cruciate retaining standard cemented prosthesis by a parapatellar medial approach, without use of tourniquet or Local Infiltration Analgesia.

For the spinal anesthesia, 3 mL of Ropivacaine 5 mg/ml will be applied.

All patients will receive a femoral triangle block in combination with the PPB, both administered immediately after surgery in the post-anesthesia care unit.

Description of the PPB procedure:

The superficial femoral artery is identified at mid-thigh level and traced caudally until it deviates from sartorius muscle and is positioned adjacent to the posteromedial margin of the vastus medialis muscle, close to the adductor hiatus. The needle will be inserted medially to the transducer and advanced in-plane through the sartorius muscle targeting the endpoint of injection in the distal part of the adductor canal, on the top of the superficial femoral artery, posteromedial to the fascia of the vastus medialis muscle. We will inject the allocated volume of bupivacaine 5 mg/mL, ensuring anterolaterally spread to the artery

The Femoral Triangle Block uses 15 mL of Bupivacaine 5 mg/mL (10 mL applied in the femoral triangle to target the saphenous nerve and nerve to vastus medialis and 5 mL applied to target the intermediate femoral cutaneous nerve located at the superficial side of the sartorius muscle).

The multimodal analgesic regime also consists of a Dexamethasone 12 mg IV (administered perioperatively), Paracetamol (1000 mg) x 4 daily + NSAID (400 mg) x 3 times daily postoperatively, inclusing preoperatively administration of Paracetamol 1000 mg and Ibuprofen 400 mg.

The scored morphine tablets allows the patients to take 5 mg morphine at a time, with a maximum oral dose of 100 mg within the first 24 hours after end-of-surgery time. If needed, hospital staff can administer rescue doses of intravenous morphine, which will be recorded in the patient file. Total opioid consumption will be reported as oral morphine milligram equivalents (MME), combining hospital-administered opioid doses from the patient file and self-reported intake of dispensed morphine tablets.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Total Knee Arthroplasty Regional Anesthesia Multimodal Analgesic Approach Postoperative Opioid-related Complications

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This single-centre, blinded, controlled, randomized clinical trial follows a parallel design, with one group receiving a PPB with 10 mL of bupivacaine 5 mg/mL and the other group receiving a PPB with 20 mL of bupivacaine 5 mg/mL. A total of 120 patients will be included and allocated in a 1:1 ratio using computer-generated block randomization (blocks of 10).
Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors
Good-Clinical-Practice monitor is also blinded.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Popliteal Plexus Block with 20 mL of bupivacaine

Group Type EXPERIMENTAL

Bupivacaine

Intervention Type DRUG

Applied perineurally using a 22-gauge, 80-mm block needle (Temena, Felsberg, Germany) under ultrasound guidance.

Popliteal Plexus Block with 10 mL of bupivacaine

Group Type ACTIVE_COMPARATOR

Bupivacaine

Intervention Type DRUG

Applied perineurally using a 22-gauge, 80-mm block needle (Temena, Felsberg, Germany) under ultrasound guidance.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bupivacaine

Applied perineurally using a 22-gauge, 80-mm block needle (Temena, Felsberg, Germany) under ultrasound guidance.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Scheduled to undergo primary total knee arthroplasty in spinal anesthesia.
* Ability to give their written informed consent after having fully understood the contents of the study.
* American Society of Anesthesiologists (ASA) physical status 1, 2, or 3.

Exclusion Criteria

* Patients who cannot read or speak Danish.
* Patients who cannot operate or have access to a smartphone with internet connectivity (required for patient-reported outcome assessment).
* Patients with allergies or intolerance to the medicines used in the study.
* Patients with a consistent daily intake of opioids preoperatively.
* Patients who are dependent on walking aid devices preoperatively.
* Patients suffering from alcohol and/or drug abuse - based on the investigator's assessment.
* BMI \> 40.
* Diagnosed with chronic neurodegenerative disorders.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Regionshospitalet Silkeborg

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Johan Kløvgaard Sørensen

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Johan K Sørensen, MD

Role: PRINCIPAL_INVESTIGATOR

Elective Surgery Centre at Silkeborg Regional Hospital, Denmark

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Elective Surgery Centre at Silkeborg Regional Hospital

Silkeborg, Denmark Central Region, Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

References

Explore related publications, articles, or registry entries linked to this study.

Sorensen JK, Jensen MSH, Grevstad U, Nikolajsen L, Runge C. Optimal Analgesic Volume for Popliteal Plexus Block After Total Knee Arthroplasty: A Blinded RCT Protocol. Acta Anaesthesiol Scand. 2025 Jul;69(6):e70057. doi: 10.1111/aas.70057.

Reference Type DERIVED
PMID: 40346895 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2024-520204-26-00

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Multimodal Pain Management Following Primary TKA
NCT02369523 TERMINATED EARLY_PHASE1
Liposome Bupivacaine for ANKLE Blocks
NCT03106545 COMPLETED PHASE2